COMP <GO>
AVIR vs TTRX // EV/EBITDA & P/E VALUATION
Atea Pharmaceuticals Inc. (NASDAQ) VS. Turn Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AVIR 2
— TTRX 2
■ METRIC PARITY
LAST: $4.31 (+0.94%) • MKT CAP: $345.7M
valuation
—
LAST: $10.72 (-3.60%) • MKT CAP: $327.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVIR VS. TTRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AVIR | TTRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -28.30% | -6.70 | TTRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -0.78% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | AVIR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.4 | 43.4 | -10.98 | TTRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $345.7M | $327.3M | $18.4M | AVIR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AVIR REV | TTRX REV | AVIR GROSS % | TTRX GROSS % | AVIR FCF | TTRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$132.0M | -$2.6M |
| FY 2024 | $0 | $0 | — | — | -$135.5M | -$1.4M |
| FY 2023 | $0 | — | — | — | -$85.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVIR // BETA —
TTRX // BETA —